views
The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030.
Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.
Gather more insights about the market drivers, restrains and growth of the Blood Screening Market
The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.
The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly.
Blood Screening Market Segmentation
Grand View Research has segmented the global blood screening market based on technology, product, and region:
Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing
• Western Blotting
Product Outlook (Revenue, USD Million, 2018 - 2030)
• Reagent
• Instrument
Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Norway
o Denmark
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa
o Saudi Arabia
o South Africa
o UAE
o Kuwait
Browse through Grand View Research's Medical Devices Industry Research Reports.
• The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030.
• The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030.
Key Companies & Market Share Insights
Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.
For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.
Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.
Key Blood Screening Companies:
• Abbott
• Danaher Corporation (Beckman Coulter)
• Becton Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Hoffman-La Roche Ltd.
• Grifols, S.A.
• Ortho-Clinical Diagnostics, Inc.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific, Inc.
• SOFINA s.a (Biomerieux)
Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.
Comments
0 comment